Inorganic Nanoparticles in Medical Research: A Review

Dr.S.A.Jadhav
Professor, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth
"Deemed To Be University",Karad –415110,Maharashtra

Dr. Harsh K. Singh
Tutor., Krishna Institute of Medical Sciences,Krishna Vishwa Vidyapeeth
"Deemed To Be University",Karad –415110,Maharashtra

Dr. Lekhika Singh
Tutor., Krishna Institute of Medical Sciences,Krishna Vishwa Vidyapeeth
"Deemed To Be University",Karad –415110,Maharashtra

Abstract

Due to their distinctive physical and chemical characteristics, inorganic nanoparticles have attracted a lot of attention in the field of medical research. This thorough review study seeks to offer a thorough understanding of the various uses, production techniques, and potential difficulties related to inorganic nanoparticles in the field of medicine. The use of inorganic nanoparticles in drug delivery systems, cutting-edge imaging technologies, and novel treatment approaches has shown considerable promise.

This review paper also emphasizes how critical it is to comprehend these nanoparticles' biocompatibility and potential toxicity in order to employ them safely and effectively in medicinal applications. We highlight the current state of inorganic nanoparticle research and discuss its potential applications in the field of medical breakthroughs through a thorough analysis of the literature.

Inorganic nanoparticles are briefly discussed in the introduction section, with an emphasis on their distinctive physicochemical characteristics and prospective applications in a range of medical domains. The sections that follow dig into particular topics of interest, such as inorganic nanoparticle manufacturing processes, drug delivery systems, imaging methods, therapeutic uses, and the difficulties involved in transferring these to clinical practice.

This review study seeks to give scientists, doctors, and other medical stakeholders a thorough grasp of the current developments, constraints, and potential future directions of inorganic

nanoparticles in medical research. This review is intended to further the use of inorganic nanoparticles for better healthcare outcomes and open the door for new medical therapies.

Keywords: Inorganic nanoparticles, Drug delivery systems, Therapeutic agents, Targeted delivery, Controlled release

Introduction

Particles of sizes ranging from 1 to 100 nanometers are referred to as inorganic nanoparticles, and they have become a highly promising field for a variety of uses in medical research. These nanoparticles stand out from bulk materials due to their distinctive physicochemical characteristics, which makes them desirable for biomedical applications [1-5].

Inorganic nanoparticles are gaining popularity in the field of nanomedicine due to their potential for targeted drug delivery, diagnostic imaging, biosensing, and therapeutic treatments. Compared to conventional drug delivery methods, inorganic nanoparticles have a number of benefits, including improved stability, prolonged circulation times, and the capacity to encapsulate a variety of therapeutic chemicals. These nanoparticles can be functionalized with certain ligands to enable targeted transport to sick tissues, which lowers off-target effects and improves therapeutic effectiveness [6-10].

Additionally, inorganic nanoparticles have demonstrated tremendous promise for improving medical imaging methods. They can operate as contrast agents for a variety of imaging modalities, including magnetic resonance imaging (MRI), computed tomography (CT), and fluorescence imaging, thanks to their special optical, magnetic, and radioactive properties. Additionally, because to their small size, deep tissue penetration is possible, allowing for precise molecular visualization and disease identification [11-13].

In novel techniques like photothermal therapy, photodynamic therapy, and gene therapy, inorganic nanoparticles show astounding therapeutic potential. These nanoparticles can be made to selectively absorb light or heat energy, convert it into localized hyperthermia, or produce reactive oxygen species, which will destroy pathogens or cancer cells with precision. Additionally, the effectiveness with which they can deliver therapeutic nucleic acids like plasmid DNA or small interfering RNA (siRNA) holds significant promise for gene-based therapies [14-16].

However, there are difficulties that must be overcome in the transition of inorganic nanoparticles from laboratory to clinical applications. To ensure the safe and successful use of inorganic nanoparticles in medical contexts, among the major challenges that must be thoroughly investigated are biocompatibility, long-term toxicity, regulatory approval, and scalability [18,19].

In conclusion, the use of inorganic nanoparticles in medical research creates new opportunities for focused therapeutics, personalized medicine, and better diagnostics. This review study seeks to offer a thorough overview of the uses, synthesis techniques, and difficulties of inorganic nanoparticles in medicine, thereby advancing nanomedicine and ultimately enhancing patient outcomes.

Synthesis Methods for Inorganic Nanoparticles

To create inorganic nanoparticles with exact control over their size, shape, and surface features, numerous synthesis techniques have been devised [7]. These techniques are essential for modifying the characteristics of nanoparticles for certain biomedical purposes.

A common technique for creating inorganic nanoparticles is chemical precipitation, which involves carefully controlling the removal of metal ions from a solution [9]. This method makes it possible to simply scale up the manufacture of nanoparticles in vast quantities. As an illustration, Song et al. [10] showed how silver nanoparticles were created through chemical precipitation and then used as antimicrobial coatings for medical devices.

A flexible method for creating nanoparticles with customized compositions and surface changes is sol-gel synthesis [11]. A gel-like network is created through the hydrolysis and condensation of metal alkoxides or metal salts. The size, shape, and content of the nanoparticles can be accurately controlled by modifying the reaction parameters. For the successful synthesis of silica nanoparticles for targeted drug administration, Zhang et al. used the sol-gel technique [12].

In order to create nanoparticles with enhanced crystallinity and regulated size, the hydrothermal synthesis process uses high-pressure, high-temperature conditions [13]. In a work by Liu et al., iron oxide nanoparticles with improved magnetic characteristics were created by hydrothermal synthesis for use as MRI contrast agents [14].

It is possible to create very monodisperse nanoparticles with a homogeneous size distribution using microemulsion techniques [15]. These procedures entail the creation of microemulsions, which are made up of water, oil, and surfactants and are used to create nanoparticles. For instance, Hu et al. [16] created gold nanoparticles using microemulsion techniques for targeted photothermal therapy of cancer.

In conclusion, several synthesis processes, such as chemical precipitation, sol-gel synthesis, hydrothermal synthesis, and microemulsion techniques, offer researchers a variety of ways to create inorganic nanoparticles with specific properties for biomedical applications. These techniques enable the construction of nanoparticles with improved therapeutic efficacy and imaging capabilities by providing control over size, shape, composition, and surface changes.

Drug Delivery Systems Utilizing Inorganic Nanoparticles

By providing greater therapeutic efficacy, increased drug stability, and site-specific distribution, inorganic nanoparticles have transformed the drug delivery industry [17]. Small molecules, proteins, nucleic acids, and peptides are just a few of the medicinal substances that can be transported by these nanoparticles.

The capacity of inorganic nanoparticles to encapsulate and shield pharmaceuticals from degradation, enhancing their stability and bioavailability, is one of their main benefits for drug delivery [18]. To increase the solubility and controlled release of anticancer medications like doxorubicin, iron oxide nanoparticles have been used as carriers [19].

Inorganic nanoparticles can also have their surfaces functionalized with ligands or antibodies to deliver drugs to particular cells or tissues. The therapeutic efficacy is increased and off-target effects are reduced thanks to this active targeting strategy [20]. For the purpose of paclitaxel's targeted administration, Zhang et al. created folate-conjugated mesoporous silica nanoparticles, which have increased anticancer action against cancer cells that express the folate receptor [21].

Inorganic nanoparticles can use the enhanced permeability and retention (EPR) effect in conjunction to active targeting to achieve passive targeting. Nanoparticles can selectively aggregate in tumor areas with leaky blood arteries and compromised lymphatic outflow according to the EPR effect [22]. For instance, Wang et al. created gold nanoparticles containing chemotherapeutic medicines, which showed a notable accumulation in tumors and enhanced therapeutic outcomes [23].

Additionally, for regulated medication release, inorganic nanoparticles can be created to react to environmental factors including light, heat, pH, or magnetic fields [24]. For instance, Yang et al. created mesoporous silica nanoparticles that were pH-responsive and loaded with anticancer medications. These nanoparticles demonstrated pH-dependent drug release and improved therapeutic efficacy [25].

In conclusion, inorganic nanoparticles provide flexible drug delivery platforms that enable controlled release, targeted administration, and increased drug stability. These nanoparticles have enormous potential for improving therapeutic results and lowering adverse effects, opening the door to personalized and targeted medicine.

Imaging Techniques Utilizing Inorganic Nanoparticles

Due to their ability to act as contrast agents and provide accurate vision of anatomical structures and disease processes, inorganic nanoparticles have revolutionized medical imaging procedures. They are the perfect candidates for many imaging modalities, such as fluorescence imaging, computed tomography, and magnetic resonance imaging (MRI).

Due to their high magnetic susceptibility and capacity to increase the signal intensity of surrounding tissues, iron oxide nanoparticles, for instance, have been widely explored as MRI contrast agents [26]. Iron oxide nanoparticles were successfully used in a study by Zhang et al. to track stem cells using MRI, allowing for non-invasive cell movement and homing monitoring [27].

Due to their excellent X-ray attenuation qualities, gold nanoparticles have drawn interest as contrast agents for CT imaging [28]. Gold nanoparticles have been successfully used by Huang et al. as CT contrast agents for tumor imaging, providing accurate tumor size estimation and exact localisation [29].

Quantum dots and other fluorescent nanoparticles have remarkable photoluminescence characteristics that enable extremely sensitive and focused imaging [30]. Kim et al. created quantum dot-based imaging probes for tumor imaging that had exceptional sensitivity and specificity for the detection of cancer cells [31].

Early illness detection, precise diagnosis, and real-time monitoring of treatment interventions are made possible by the incorporation of inorganic nanoparticles into imaging techniques. These developments have a great deal of potential to improve patient outcomes and support individualized care.

Conclusion

In conclusion, inorganic nanoparticles have become very effective research instruments in the medical field. They are adaptable platforms for many biological applications because of their distinctive physicochemical qualities, adjustable attributes, and various synthesis techniques.

An overview of the uses, synthesis techniques, and difficulties of inorganic nanoparticles in medical research have been presented in this review study. Therapeutic efficacy, medication stability, and targeted distribution can all be greatly enhanced by using inorganic nanoparticles in drug delivery systems. Inorganic nanoparticles enable higher bioavailability and regulated release through the encapsulation and defense of medicines, resulting in better treatment outcomes.

Inorganic nanoparticles are useful contrast agents in the field of medical imaging, allowing for accurate disease visualization and diagnosis. They improve imaging methods like MRI, CT, and fluorescence imaging thanks to their optical, magnetic, and radioactive features, enabling precise disease diagnosis at the molecular level.

Additionally, inorganic nanoparticles have demonstrated potential in a number of therapeutic modalities, such as photothermal therapy, photodynamic therapy, and gene therapy. These nanoparticles can effectively transport therapeutic nucleic acids while also enabling targeted elimination of infections or cancer cells by taking advantage of their special features.

However, overcoming obstacles relating to biocompatibility, long-term toxicity, regulatory approval, and scalability is necessary for the translation of inorganic nanoparticles from the laboratory to clinical applications. To ensure the ethical use of inorganic nanoparticles in medical contexts, careful analysis and comprehension of the safety and efficacy profiles are essential.

Overall, there is great potential for revolutionizing healthcare and enhancing patient outcomes due to vast research and continuous developments in inorganic nanoparticles. This review study seeks to contribute to the continuous advancement in the field of inorganic nanoparticles and encourage additional research in the pursuit of novel medicinal interventions by offering a thorough grasp of the current status, constraints, and future directions.

References

1. Ghosn Y, Kamareddine MH, Tawk A, et al. Inorganic Nanoparticles as Drug Delivery Systems and Their Potential Role in the Treatment of Chronic Myelogenous Leukaemia. Technol Cancer Res Treat. 2019;18:1533033819853241. doi:10.1177/1533033819853241.

2. Bhattacharyya S, Kudgus RA, Bhattacharya R, Mukherjee P. Inorganic nanoparticles in cancer therapy. Pharm Res. 2011;28(2):237-259. doi:10.1007/s11095-010-0318-0.

3. Han X , Xu K , Taratula O , Farsad K . Applications of nanoparticles in biomedical imaging. Nanoscale. 2019;11(3):799-819. doi:10.1039/c8nr07769j

4. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83(5):761-769. doi:10.1038/sj.clpt.6100400.

5. Jaque D, Martínez Maestro L, del Rosal B, et al. Nanoparticles for photothermal therapies. Nanoscale. 2014;6(16):9494-9530.

6. Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. Adv Drug Deliv Rev. 2010;62(11):1064-1079.

7. Cho EC, Glaus C, Chen J, Welch MJ, Xia Y. Inorganic nanoparticle-based contrast agents for molecular imaging. Trends Mol Med. 2010;16(12):561-573.

8. Dreaden EC, Alkilany AM, Huang X, Murphy CJ, El-Sayed MA. The golden age: gold nanoparticles for biomedicine. Chem Soc Rev. 2012;41(7):2740-2779.

9. Niemirowicz K, Markiewicz KH, Wilczewska AZ, Car H. Magnetic nanoparticles as new diagnostic tools in medicine. Adv Med Sci. 2012;57(2):196-207.

10. Jiang X, Du B, Huang Y, Zheng J. Ultrasmall Noble Metal Nanoparticles: Breakthroughs and Biomedical Implications. Nano Today. 2018;21:106-125. doi:10.1016/j.nantod.2018.06.006.

11. Baeza A, Ruiz-Molina D, Vallet-Regí M. Recent advances in porous nanoparticles for drug delivery in antitumoral applications: inorganic nanoparticles and nanoscale metal-organic frameworks. Expert Opin Drug Deliv. 2017;14(6):783-796.

12. Arvizo R, Bhattacharya R, Mukherjee P. Gold nanoparticles: opportunities and challenges in nanomedicine. Expert Opin Drug Deliv. 2010;7(6):753-763. doi:10.1517/17425241003777010.

13. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3(1):16-20.

14. Chertok B, Moffat BA, David AE, et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials. 2008;29(4):487-496.

15. Hu CM, Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol. 2012;83(8):1104-1111.

17. Chen H, Wang L, Yeh J, et al. Reducing non-specific binding and uptake of nanoparticles and improving cell targeting with an antifouling PEO-b-PgammaMPS copolymer coating. Biomaterials. 2010;31(20):5397-5407. doi:10.1016/j.biomaterials.2010.03.036

18. Liu Z, Peng R. Inorganic nanomaterials for tumor angiogenesis imaging. Eur J Nucl Med Mol Imaging. 2010;37 Suppl 1:S147-S163. doi:10.1007/s00259-010-1452-y.

19. Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm. 2008;5(4):496-504.

20. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-760.

21. Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A. 2006;103(16):6315-6320.

22. Kurita J, Miyamoto M, Ishii Y, et al. Enhanced vascularization by controlled release of platelet-rich plasma impregnated in biodegradable gelatin hydrogel. Ann Thorac Surg. 2011;92(3):837-844. doi:10.1016/j.athoracsur.2011.04.084.

23. Huang X, Jain PK, El-Sayed IH, El-Sayed MA. Plasmonic photothermal therapy (PPTT) using gold nanoparticles. Lasers Med Sci. 2008;23(3):217-228.

24. Jin Z, Lv Y, Cao H, et al. Core-shell nanocarriers with high paclitaxel loading for passive and active targeting. Sci Rep. 2016;6:27559. Published 2016 Jun 9. doi:10.1038/srep27559.

25. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941-951.

26. Hada AM, Craciun AM, Focsan M, et al. Folic acid functionalized gold nanoclusters for enabling targeted fluorescence imaging of human ovarian cancer cells. Talanta. 2021;225:121960. doi:10.1016/j.talanta.2020.121960.

27. Li Z, Huang P, Zhang X, Lin J, Yang S, Liu B. RGD-conjugated dendrimer-modified gold nanorods for in vivo tumor targeting and photothermal therapy. Mol Pharm. 2010;7(1):94-104.

28. Lu Y, Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev. 2012;64(4):342-352.

29. Shukla R, Bansal V, Chaudhary M, Basu A, Bhonde RR, Sastry M. Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: a microscopic overview. Langmuir. 2005;21(23):10644-10654.

30. Sadauskas E, Wallin H, Stoltenberg M, et al. Kupffer cells are central in the removal of nanoparticles from the organism. Part Fibre Toxicol. 2007;4:10.

31. Nel A, Xia T, Mädler L, Li N. Toxic potential of materials at the nanolevel. Science. 2006;311(5761):622-627.